Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine
Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.
Toggle navigation